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Abstract
Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts
are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We here report a 45-
year-old woman with de novo AMKL with BCR/ABL rearrangement and der(16)t(1;16)(q21;q23) translocation but
negative for t(9;22) Ph chromosome. Upon induction chemotherapy consisting of homoharringtonine, cytarabine
and daunorubicin, the patient achieved partial hematological remission. The patient was then switched to imatinib
plus one cycle of CAG regimen (low-dose cytarabine and aclarubicin in combination with granulocyte colony-
stimulating factor), and achieved complete remission (CR). The disease recurred after 40 days and the patient
eventually died of infection. To the best of our knowledge, this is the first report of de novo AMKL with p210 BCR/
ABL and der(16)t(1;16)(q21;q23) translocation but not t(9;22) Ph chromosome.
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Background
Acute megakaryoblastic leukemia (AMKL), also known as
M7 under the French-American-British (FAB) classifica-
tion, represents < 5% of acute myeloid leukemia (AML)
[1-3]. In adults, AMKL constitutes only 0.5% - 1% of de
novo AML cases [4]. Ph chromosome is a rare cytogenetic
abnormality (≈ 1%) in AML [5,6]. The incidence of t(9;22)
in AMKL varies considerably in the literature: from < 20%
to > 60%, possibly due to inconsistency in the inclusion/
exclusion of blastic phase of chronic myeloid leukemia
(CML)[7-9].
Here, we report a case of 45-year-old woman with de
novo AMKL. Multiple reverse transcription-polymerase
chain reaction (RT-PCR) and Fluorescence in situ hybridi-
zation (FISH) data indicating a BCR/ABL rearrangement,
cytogenetics for der(16)t(1;16)(q21;q23) but not t(9;22) Ph
chromosome. Upon induction chemotherapy consisting of
homoharringtonine, cytarabine and daunorubicin, the
patient achieved partial hematological remission. The
patient then received imatinib plus one cycle of CAG
regimen (low-dose cytarabine and aclarubicin in combina-
tion with granulocyte colony-stimulating factor) [10], and
achieved complete remission (CR). The disease recurred
after 40 days and the patient eventually died of infection.
The case diagnosis and management process, including
the therapies, are summarized in Table 1.
Case Presentation
A 45-year-old woman was hospitalized on May 16th, 2008
with two weeks of fatigue, dizziness and low fever. The
body temperature was 37.9°C. On auscultation, a II/VI sys-
tolic murmur was noticed over the apical region. The liver
was palpable at 2 cm below the ribcage. The spleen was
palpable at 2 cm below the left costal margin. Abdominal
ultrasound confirmed slight hepatosplenomegaly. The
patient had no history of toxic substance exposure. Family
history was non-remarkable.
Blood tests revealed a hemoglobin concentration of
63 g/L, a hematocrit of 23%, a platelet count of 138 ×
10
9/L. White blood cell count was 24 × 10
9/L, with 54%
megakaryoblasts, 17% promegakaryocytes, 10% myelo-
cytes, 8% band forms, 7% neutrophils, 3% lymphocytes,
and 1% monocytes. Plasma D-dimer and lactate dehydro-
genase (LDH) were normal. A bone marrow smear
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cytes. The megakaryoblasts were medium to large-size
with round, slightly irregular nuclei and one to three
nucleoli (Figure 1a). The cytoplasm of promegakaryocytes
was basophilic and might show distinct pseudopod forma-
tion (Figure 1b). Immunohistochemistry staining (Leuko-
cyte Phenotyping Kit, Sun BioTech, China) of these cells
revealed a total of 55% positivity for CD41 (Figure 1c) and
60% positivity for CD42b (Figure 1d), while CD13, CD14,
CD68, MPO, HLA-DR, CD10, CD19, CD3, CD5, and CD7
were all negative A bone marrow biopsy indicated acute
leukemia with myelofibrosis (Figure 1e &1f).
Cytogenetic analysis of trypsin R-banded chromosome
preparations revealed 46, XX, der(16)t(1;16)(q21;q23)[8]/
46,XX [12] (Figure 2). To identify fusion genes, multiplex
reverse transcription-polymerase chain reaction (RT-PCR)
was performed with 1~8 parallel nested (2-round) multi-
plex reactions in a thermocycler (Perkin-Elmer) to achieve
maximal sensitivity, as described in a previous study [11].
The E2A mRNA was used as the internal positive control.
The groups containing possible fusion genes were further
characterized using split-out PCR to identify the fusion
pattern as described previously [11]. The results suggested
the presence of fusion among the following genes: BCR,
ABL and TEL (Figure 3a). A split-out PCR analysis was
performed using the individual primer sets BCR/ABL
e1a2, BCR/ABL b2a2 or b3a2, TEL/ABL. The results
revealed fused BCR/ABL b2a2 mRNA expression (Figure
3b). FISH analysis on interphase cells revealed an atypical
signal pattern consisting of one green signal, two orange
signals, and one orange/green (yellow) fusion signal in
approximately 30% of the cells (Figure 3c).
On the basis of the above reported clinical and biological
features, a diagnosis of de novo acute AMKL. The patient
received induction had regimen consisting of: homohar-
ringtonine (2 mg/m
2/day on day 1 - 7), cytarabine (100
mg/m
2/day on day 1 - 7) and daunorubicin (45 mg/m
2/
day on day 1 - 3). A bone marrow smear at one month
later showed no improvement. A partial remission was
achieved after the induction treatment was repeated. The
patient then received imatinib (600 mg/d, p.o.) and one
cycle of CAG regimen (cytarabine 30 mg/day for 14 days,
aclarubicin 10 mg/day on days 1 - 8, and granulocyte col-
ony-stimulating factor 300 μg/day on days 1 - 14). Imati-
nib was discontinued after 2 weeks due to severe bone
marrow suppression. Plasma LDH and liver enzymes
remained within the normal range during the treatment.
A complete hematological response was achieved upon
evaluation at 50 days after initiating imatinib treatment,
and the patient was discharged. She was hospitalized for
high fever and dyspnea after 40 days. Hemoglobin was 90
g/L. White blood cell count was 19 × 10
9/L, with 21%
blast cells. Relapse was established with bone marrow
smear. The patient was treated with cytarabine (2 g/m
2/
day on days 1 - 3) and daunorubicin (45 mg/m
2/day on
days 1 - 3), with no apparent improvement. She died of
fungal infection after 27 days.
Conclusions
Although the first AMKL was described as early as 1931,
reports have been sporadic because of both the rarity of
the disease and the lack of well-established diagnostic cri-
teria. In fact, precise diagnostic criteria were added to the
French-American-British classification only in 1985 (FAB
Table 1 The clinical course of the patient
Time Management process
d1
(3/20)
Diagnosis established;
Induction chemotherapy consisting of homoharringtonine, cytarabine and daunorubicin began.
d30 Bone marrow smear showed 20.4% megakaryoblasts and 24.8% promegakaryocytes (chemotherapy failure);
Second induction chemotherapy.
d60 Bone marrow smear showed 6% megakaryoblasts and 11% promegakaryocytes (partial remission);
Imatinib treatment started (600 mg/d) and CAG regimen
d67 WBC: 3.5 × 10
9/L.
d69 Imatinib reduced to 400 mg/d.
d75 Imatinib discontinued (WBC: 0.9 × 10
9/L).
d102 Imatinib restarted (200 mg/d);
WBC: 4.3 × 10
9/L (d106)
d107 Imatinib increased to 400 mg/d
d110: complete hematological remission
WBC:3.2 × 10
9/L (d110); 3.5 × 10
9/L (d120); 4.2 × 10
9/L (d130)
d132 Imatinib discontinued (due to financial reasons)
d150 Relapse.
d177 Patient deceased.
Abbreviations: d, day; CAG regimen: cytarabine 30 mg/day for 14 days, aclarubicin 10 mg/day on days 1 - 8, and granulocyte colony-stimulating factor 300 μg/
day on days 1 - 14; WBC, white blood cell count.
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Page 2 of 7Figure 1 Diagnosis of acute megakaryoblastic leukemia. a. Bone marrow smear revealed many medium to large-size megakaryoblasts. The
yellow arrow indicates megakaryoblasts (1000 ×). b. Bone marrow smear revealed many large-size promegakaryocytes. The cytoplasm of
promegakaryocytes shows distinct pseudopod formation (1000 ×). The red arrow indicates the promegakaryocytes. c, d. Immunohistochemistry
staining of CD41 (c) and CD42b (d) of bone marrow smears (1000 ×). The positivity was shown by the red precipitates in plasma or membrane.
e. Bone marrow biopsy showing diffuse bone marrow infiltration of medium-size megakaryoblasts (1000 ×). The blue arrow indicates the
megakaryoblasts. f. Bone marrow biopsy showing myelofibrosis (100 ×). The white arrow indicates myelofibrosis.
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Page 3 of 7M7) [1]. The bone marrow aspirate shows a leukemic cell
infiltrate that comprises 30% or more of all cells. These
cells are identified as being of megakaryocyte lineage by
platelet peroxidase reaction on electron microscopy or by
tests with monoclonal or polyclonal platelet-specific anti-
bodies (CD41a, CD42 or CD61). Myelofibrosis or
increased bone marrow reticulin are a prominent aspect
in most AMKL patients. In some cases, megakaryoblastic
crisis could be the first presentation of CML, and not dis-
tinguishable from de novo AMKL [12-16]. This case
represents de novo AMKL in our opinion, because the
patient had no basophilia and eosinophilia upon presen-
tation, which are often seen in blast crisis of CML [17].
Basophilia, a frequent feature of blast crisis, is uncom-
mon in acute leukemias [18]. Furthermore, our patient
had only mild splenomegaly. Moderate or severe spleno-
megaly is common in blast crisis of CML [13,16].
AMKL is associated with no specific cytogenetic
abnormality, and the majority of cases present with a com-
plex karyotype. In a recent study by Le Groupe Francais de
Cytogenetique Hematologique (GFCH), complex karyo-
types of unbalanced changes, such as -5/del5q or -7/del
(7q), 3q21q26, dic(1;15)(p11;p11), inv(4)(p15q11), t(14;21)
(q24;q22), der(7)t(7;17)(q11;q11) and t(6;13)(p22;q14),
were common in adult de novo AMKL [8]. In addition,
the t(X;16) translocation has also been reported in 2 adult
de novo AMKL cases [8]. One translocation was 46,XY,t
(16;21)(p11;q22), another was t(16;16)(p13;q22). The pre-
sent case serves to identify a novel translocation der(16)t
(1;16)(q21;q23), providing further insight into the hetero-
geneity of genomic rearrangement in this subset of AML.
Data concerning the incidence of the Ph chromosome
or BCR/ABL rearrangement in de novo AMKL are
scarce. The Ph chromosome is one of the most common
chromosomal abnormalities associated with adult AMKL
according the report of the GFCH [8]. For example, Ph
chromosome was found in four out of a total of 23
AMKL cases (17%) [8]. In fact, only two cases were de
n o v oA M K L( 9 % ) .I na ne a r l ys t u d yo f1 4A M K L
patients with cytogenetic data, Ph chromosome was
found in two cases of megakaryoblastic transformation
of chronic myelogenous leukemia, but not in de novo
AMKL [7]. Ohyashiki et al. reported three cases with
AMKL, but none had Ph chromosome [9].
Figure 2 Representative karyogram of bone marrow cell showing the 46,XX,der(16)t(1;16)(q21;q23).
Min et al. Journal of Hematology & Oncology 2011, 4:45
http://www.jhoonline.org/content/4/1/45
Page 4 of 7Reports of Ph chromosome or BCR/ABL rearrange-
ment are summarized in Table 2. Cases were heteroge-
neous and the survival was from 1.9 to 96 months. The
case reported by Kaloutsi et al. [20] was a 24-year-old
male with de novo AMKL. Interestingly, cytogenetics
revealed a t(10;22), which by FISH, was found to be a var-
iant Philadelphia translocation involving chromosome
10q. The FISH result in our case revealed an atypical
Figure 3 Detection of fusion genes. a. Multiplex reverse transcription-PCR analysis showed that the cells of this patient were positive for a
translocation in multiplex reaction 6 (The arrow). Internal positive control: E2A (690 bp). The primer sets used in multiplex reverse transcription-
PCR were chosen as described previously [11] to detect the following fusion genes: 1. CBFb/MYH11/MLL/AFX1/AF6/ELL/E2A; 2. MLL/AF1P/AF17/
AF10/E2A; 3. PBX1/SIL/TAL1/HLF/TEL/AML1A/E2A; 4. AML1A/AMLMDSEVI/HOX11/ETO/TLS/ERG/E2A; 5. MLL/AF4/AF9/AF1Q/ENL/E2A; 6. BCR/ABL/
TEL/E2A; 7. DEK/CAN/SET/AMLMDSEVI /E2A; 8. PLZF/PML3/RARa/NPM/NPMALK /MLF1/E2A; b. The split-out PCR analysis revealed a BCR/ABL
b2a2 fusion gene expression using primer sets for 1. BCR/ABL e1a2 (320 bp); 2. BCR/ABL b2a2 (472 bp) and BCR/ABL b3a2 (397 bp); 3. TEL/ABL
(366 bp); c. Fluorescence in situ hybridization (FISH) using a Vysis LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe (Vysis, Downers Grove,
IL, USA) on an interphase cell. Orange signal is ABL gene on chromosome 9 and green signal is BCR gene on chromosome 22. The ABL orange
signals occurred on both chromosomes 9 and on der(9)ins(22;9) and one BCR green signal on chromosomes 22 and one yellow fusion signal on
der(22)ins(22;9). The arrow indicates the fusion signal.
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Page 5 of 7Table 2 Literature review of Ph chromosome or BCR/ABL rearrangement in de novo acute megakaryoblastic leukemia
Case No. Sex/Age (years) Cytogenetic changes BCR/ABL fusion transcripts Survival (month) Reference
1 F/58 47,XX,+8,t(9;22)(q34;q11) P190 BCR/ABL 6 Balatzenko, et al[19]
2 F/72 46,XX,t(9;22)(q34;q11)[12]/(4n) 92,XXXX,t(9;22)x2 [10]/(8n)184,XXXXXXXX,t(9;22)x4 [4] Not provided 27 Dastugue, et al [8]
3 F/51 46,XX,t(9;22)(q34;q11)[25] Not provided 27 Dastugue, et al [8]
4 F/44 46,XX,inv(3)(q21q26)[4]/46,idem,t(9;22)(q34;q11)[15] Not provided 1.9 Dastugue, et al [8]
5 M/24 46,XY,t(10;22)(q26;q11)
FISH: t(9;22);10q
Not provided Not provided Kaloutsi, et al [20]
6 M/53 46,XX,t(9;22)(q34;q11),del(18)(p10)[15] BCR/ABL e6a2 96 Corm, et al [21]
7 M/39 t(9;22)(p24.1;q12.2)
t(8;17)(q23;q24.2).
Not provided Not provided Ahmad, et al [22]
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7signal pattern: one yellow fusion signal with one green
and two orange signals (Figure 3c). This result confirmed
that the detected variant translocation involved frag-
ments of two chromosomes: 9 and 22. The ABL orange
signals occurred on both chromosomes 9 and on der(9)
ins(22;9) and one BCR green signal on chromosomes 22
and one yellow fusion signal on der(22)ins(22;9).
To the best of our knowledge, this is the first report of
de novo AMKL with rare variant of Philadelphia rear-
rangement and a novel translocation der(16)t(1;16)(q21;
q23). Our case and the case reported by Kaloutsi et al.
[20] suggested that the FISH should be considered for
detection of variant Philadelphia rearrangement in de
novo AMKL patients.
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